New staining technique could sharpen healing assessment in IBD
NCT ID NCT07710287
First seen Jul 17, 2026 · Last updated Jul 17, 2026
Summary
This study tests whether a new laboratory method—staining for a protein called claudin 2—can more accurately measure healing in the gut of people with ulcerative colitis or Crohn's disease. Researchers will compare this method with standard scoring systems and track whether it predicts relapses, hospital stays, or surgery over one year. The goal is to improve how doctors assess disease activity and guide treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a more accurate way to measure healing in IBD, helping predict relapses and guide treatment decisions.
- What could go wrong
- This is an observational study, not a treatment trial. The new method may not prove more accurate than existing scores, and results may not change clinical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2025
- Expected to finish
-
Sep 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Consecutive patients with IBD recruited at the IBD Unit of the Gastroenterology Department of IRCCS San Donato POliclinic
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Confirmed diagnosis of IBD Exclusion Criteria: Unconfirmed diagnosis of IBD
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Crohn disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Gastroenterology IRCCS San Donato Policlinic
RECRUITINGSan Donato Milanese, Mi, 20097, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune aging blood tests predict which older IBD patients thrive on advanced therapies?
- Triple-Pronged attack on gut inflammation put to the test
- Two biologics go head to head in ulcerative colitis
- Can a liquid diet calm Crohn's in kids?
- New drug ATTO-1091 put to the test for safety in ulcerative colitis
- Antiparasitic drug tested as new weapon against ulcerative colitis